BRCA1 R1699Q, a point mutation found in non-familial breast cancer patients, results in the failure of BRCA1 to recruit HDAC2 to the miR-155 promoter leading to histone acetylation and a subsequent increase in miR-155 expression contributing to breast tumourigenesis [10]. The gene discussed is HDAC2; the disease is breast carcinoma.